MORTALITY AND MORBIDITY IN HEMODIALYSIS PATIENTS

描述(直接取自应用程序) 美国患者的总死亡率(美国)在结束的时候- 血液透析(HD)治疗的阶段性肾病(ESRD)增加 在过去的十年里。接受HD治疗的患者的预期寿命为 在目前的死亡率下，只有20%的总人口。 与发病率和死亡率相关的变量必须包括 哪些是与治疗相关的(透析量、膜 类型)和与患者相关的(年龄、性别、并存 疾病)，但这些变量还没有在 人口众多。这个项目的目标是进行一项 前瞻性、多中心、随机临床试验，将检查 不同透析量和膜成分对透析效果的影响 根据HD患者的死亡率和发病率。实验设计 是一个2乘2的析因研究。在一系列的筛选测试之后， 包括评估提供高剂量水平的 向每一位潜在参与者提供透析，参与者将 随机接受两种水平的透析中的一种，按2- 池可变容量KT/V：0.95vs1.4，并根据需要进行透析 低通量纤维素膜或高通量合成或 半合成膜。这四个组的死亡率将分别为 主要结果是。一系列次要结果，包括 住院频率、感染和心脏评估 并发症、营养和一般健康及发病率评估 也将接受评估。止痛点包括透析不足、不良反应 透析膜的反应、移植及结论 随访期。

DESCRIPTION (Directly taken from the application) The gross mortality of patients in the United States (U.S.) with end- stage renal disease (ESRD) treated by hemodialysis (HD) has increased over the past decade. Patients treated by HD have a life expectancy of only 20 percent of the general population at the current mortality rate. The variables associated with morbidity and mortality must include those which are treatment related (amount of dialysis delivered, membrane type) and those which are patient related (age, gender, comorbid illness), yet these variables have not been prospectively evaluated in a large population. The goal of this project is to conduct a prospective, multi-center, randomized clinical trial which will examine the impact of different levels of dialysis dose and membrane composition upon the mortality and morbidity of HD patients. The experimental design is a two-by-two factorial study. Following a series of screening tests, including assessing the ability of delivering the high dose level of dialysis to each prospective participant, participants will be randomized to receive one of two levels of dialysis as measured by 2- pool variable volume KT/V: 0.95 vs 1.4, and to be dialyzed against either low flux cellulosic membranes or high flux synthetic or semisynthetic membranes. Mortality in each of the four groups will be the primary outcome. A series of secondary outcomes including hospitalization frequency, assessment of infectious and cardiac complications, nutritional and general health and morbidity assessment will also be evaluated. Stop points include inadequate dialysis, adverse reaction to the dialysis membrane, transplantation and conclusion of the follow-up period.